Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 17Lymphoma 16Multiple Myeloma 13Neoplasm Metastasis 10Leukemia, Myeloid, Acute 10Melanoma 9Lung Neoplasms 9Prostatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, Non-Hodgkin 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neuroblastoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Follicular 4Burkitt Lymphoma 4Wilms Tumor 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Sarcoma 3Rhabdoid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Ovarian Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

fludarabine phosphate 19Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 15Tacrolimus 12Cyclosporine 11Cyclophosphamide 11Antilymphocyte Serum 11Busulfan 10Rituximab 7Methotrexate 7Etoposide 6Melphalan 5Flow Cytometry 5Radiotherapy 4Panobinostat 4Lenalidomide 4Filgrastim 4Everolimus 4Dexamethasone 4Calcium Dobesilate 4thymoglobulin 3romidepsin 3pembrolizumab 3mogamulizumab 3fludarabine 3Therapeutics 3Sirolimus 3In Situ Hybridization, Fluorescence 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sezary Syndrome × Biopsy × Clear all
NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

National Cancer Institute (NCI)

Phase 1/2 Terminated
8 enrolled 8 charts
Lymphoid

Mycosis Fungoides, Sezary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡